亚辉龙回复上交所问询函，称与脑机星链合作产品尚未取得医疗器械注册证

Core Viewpoint - The company Aihuilong (688575) has responded to an inquiry from the Shanghai Stock Exchange regarding its recent strategic cooperation with Shenzhen Brain Machine Starlink Technology Co., Ltd. [1] Group 1: Strategic Cooperation - Aihuilong has signed a Strategic Cooperation Framework Agreement with Brain Machine Starlink, which was established in September 2025 with a registered capital of 5 million yuan [1] - The main business of Brain Machine Starlink includes comprehensive diagnosis, treatment, and rehabilitation of brain diseases [1] - The cooperation will involve market promotion and revenue sharing [1] Group 2: Product Development and Regulatory Status - The products intended for cooperation have not yet obtained medical device registration certificates, with the earliest potential product being a vagus nerve stimulator, pending final approval [1] - There is uncertainty regarding the approval of the product, and if approved, the earliest revenue generation is expected no earlier than November 2026 [1] - The sales performance of the product post-launch will depend on market conditions, and there is uncertainty regarding the conversion of sales channel resources [1] Group 3: Financial Implications - Aihuilong indicated that the cooperation with Brain Machine Starlink will not have a significant impact on its business due to the latter's short establishment time and small scale [1] - The company may consider equity investments or joint ventures to support further research and development, but any investment is expected to be small and not significantly impactful [1]